Pay in 4 interest-free payments of $18.75 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
InChi: InChI=1S/C34H36F3NO13/c1-4-5-9-21(40)49-13-20(39)33(47)11-16-24(19(12-33)51-22-10-17(27(41)14(2)50-22)38-32(46)34(35
Formula: C25H28N6O
InChi: InChI=1S/C22H23N5O2
TK216 exhibits antilymphoma activity
Boehmerle W
Sunitinib - CAS# 557795-19-4 Size:Solid 10 mg InChi: InChI=1S/C34H36F3NO13/c1-4-5-9-21(40)49-13-20(39)33(47)11-16-24(19(12-33)51-22-10-17(27(41)14(2)50-22)38-32(46)34(35Sunitinib free base is an oral, small molecule, multi targeted receptor tyrosine kinase (RTK) inhibitor. Sunitinib malate salt was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib inhibits cellular signaling by targeting multiple receptor tyrosine kinases (RTKs). The simultaneous inhibition of these targets therefore reduces tumor
US$ 13.09
US$ 29.99
US$ 14.99